Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Paxman

58.70 SEK-1.84 %23/9 10:22
Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.84 %
+6.73 %
+17.40 %
+33.41 %
+4.45 %
-17.79 %
+76.28 %
+23.58 %
+438.53 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Read more
Market cap
1.37B SEK
Turnover
81.96K SEK
Revenue
313.35M
EBIT %
1.36 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20/11
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-08-25 17:51

DNB Carnegie Access: Paxman: IBBM wheels keep on turning – Q2 review

Paxman
Press release2026-08-24 12:08

Redeye: Paxman (Q2 Review): Strong report boosts confidence in the outlook

Paxman
Press release2026-08-21 11:00

PAXMANs presentation av rapporten för det andra kvartalet 2026 finns nu tillgänglig att se i efterhand.

Paxman

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-21 11:00

PAXMAN's presentation of the Q2 2026 report is now available to watch on demand.

Paxman
Press release2026-08-21 07:41

DNB Carnegie Access: Paxman: IBBM delivers – Q2 initial

Paxman
Regulatory press release2026-08-21 07:00

PAXMAN publishes its interim report for Q2 2026.

Paxman
Regulatory press release2026-08-21 07:00

PAXMAN publishes its interim report for Q2 2026

Paxman
Press release2026-08-17 16:10

Inbjudan: Livesänd presentation med Richard Paxman – Q2 2026

Paxman
Press release2026-08-17 16:10

Invitation: Live Presentation with Richard Paxman – Q2 2026

Paxman
Press release2026-08-10 16:23

DNB Carnegie Access: Paxman: FDA says De Novo is the appropriate route for CIPN device

Paxman
Press release2026-08-10 14:20

PAXMAN meddelar regulatorisk utveckling för Limb Cryocompression System efter återkoppling från FDA

Paxman
Press release2026-08-10 14:20

Paxman Announces FDA Regulatory Progress for Limb Cryocompression System

Paxman
Press release2026-08-10 11:01

DNB Carnegie Access: Paxman: Beyond Dignitana – Q2 preview

Paxman
Press release2026-07-16 16:54

DNB Carnegie Access: Paxman: CMS proposed rules – directionally positive

Paxman
Press release2026-07-16 16:00

CMS föreslår viktig förändring av Medicare-ersättningen för mekanisk skalpkylning

Paxman
Press release2026-07-16 16:00

CMS Proposes Important Medicare Payment Policy Change for Mechanical Scalp Cooling

Paxman
Press release2026-07-14 09:33

DNB Carnegie Access: Paxman: CIPN regulatory clearance in the EU and UK

Paxman
Press release2026-07-14 09:00

Paxman utökar regulatoriska certifieringar för kryokompressionssystem för förebyggande av kemoterapiinducerad perifer neuropati (CIPN)

Paxman
Press release2026-07-14 09:00

Paxman Expands Global Regulatory Certifications for Cryocompression Device for Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

Paxman
Regulatory press release2026-05-22 11:05

Kommuniké från årsstämma i PAXMAN AB (publ)

Paxman